Stem Cell Therapy Market Research Report—Global Forecast till 2027

Stem Cell Therapy Market Growth, Trends and Size Analysis by Cell Source (Adipose Tissue, Bone Marrow, Neural, Embryo/Cord, IPSCs, and PPSCs), by Type (Autologous and Allogenic), by Application (Cancer, Diabetes, Musculoskeletal Disorders, Cardiovascular, Gastrointestinal Diseases), by End User (Hospitals & Clinics, Ambulatory Surgical Centers, Academic & Research Centers), and by Region (Americas, Europe, Asia-Pacific, and Rest of the World)—Forecast till 2027

ID: MRFR/HC/4961-CR | | Region: Global | 132 pages

Stem Cell Therapy Market

Stem Cell Therapy Market is projected to register a healthy CAGR of over 10.74% during the assessment era from 2020 to 2027.

Segmentation

By Cell Source Adipose Tissue Bone Marrow Neural Embryo/Cord IPSCs PPSCs
By Type Autologous Allogenic
By Application Cancer Diabetes Musculoskeletal Disorders Cardiovascular Gastrointestinal Diseases
By End User Hospitals & Clinics Ambulatory Surgical Centers Academic & Research Centers

Key Players

  • Seraxis Inc. (Germany)
  • ViaCyte Inc. (US)
  • Betalin Therapeutics Ltd (Israel)
  • NextCell Pharma AB (US)
  • Kadimastem (Israel)
  • Vertex Pharmaceuticals (US)
  • Fresenius Medical Care AG & Co. KGaA (Germany)
  • Sernava Corp (Canada)
  • Novo Nordisk A/S (Denmark)
  • Generex Biotechnology (Canada)

Drivers

  • Increasing prevalence of chronic disorders
  • Growing Pharmaceutical industry and increasing spending in medical research
  • Increase in the number of clinical studies for stem cell therapy
Speak to Analyst Request a Free Sample

Stem Cell Therapy Market Overview


As per the research reports by MRFR, the global stem cell therapy market is projected to register a healthy CAGR of over 10.74% during the assessment era from 2020 to 2027.


Stem cell therapy refers to a procedure that uses stem cells to prevent or treat any disease or condition. The global market for stem cell therapy has registered enormous growth in the last few years. The market's growth is primarily attributed to the increasing prevalence of chronic disorders across the globe. Furthermore, the growing spending on medical research and expanding pharmaceutical industry is also anticipated to catalyze the growth of the stem cell therapy market over the forecasted era. Moreover, the market has witnessed heavy investments for research & development activities for building a well-developed healthcare infrastructure across the developing nations, which in turn is boosting the growth of the stem cell therapy market. On the other hand, the safety issues and ethical concerns are likely to impede the market's growth over the coming years. In addition, the high cost associated with stem cell therapy is also likely to restrict the market's growth.


COVID-19 Analysis


The COVID-19 has created a new opportunity for stem cell therapy. There are several stem cell-based regenerative medicine therapy clinical trials being carried for COVID-19 patients. Clinical trials are considered as an irreplaceable aspects of the pharmaceutical industry, and it is also a greatest hope for patients suffering from diseases.


Stem Cell Therapy Market Dynamics


Market Drivers



  • Increasing prevalence of chronic disorders


The increasing prevalence of chronic disorders is propelling the demand for effective treatment. Chronic diseases such as heart disease, stroke, cancer, and respiratory diseases, along with the ongoing COVID-19 pandemic, account for a substantial burden. The Center for Disease Control (CDC) in 2019 states that six in ten adults suffer from chronic disease while four in ten suffer from more than two chronic diseases. The data demonstrates the rising burden in terms of diseases and the effective management of these diseases.



  • Growing pharmaceutical and increasing spending in medical research

  • Rising number of clinical studies for stem cell therapy


Market Restraints



  • Ethical concerns and safety issues related to embryonic stem cell-based therapy


Although stem cell research offers great promises for the medical industry, the growth in stem cell research is restricted due to ethical challenges. One of the major challenges that may have limited the development of stem cell research includes the destruction of the human embryo.


Market Opportunities



  • Growing adoption of stem cell services


The rising incidence of life-threatening genetic disorders and chronic diseases has led to an increase in the demand for stem cell banking. In addition, increasing awareness for stem cell therapy has also led to an increasing number of players entering the stem cell banking market.


Global Stem Cell Therapy Market Share (%), by Cell Source, 2020
Stem Cell Therapy Market Share by Cell Source 2020
Source: MRFR Analysis


Value Chain Analysis


The value chain analysis for the stem cell therapy market comprises five major components that start with the research & product development, followed by manufacturing the products, distribution, sales, and post-sales services. The key market players focus on incorporating innovations in their current techniques to keep any discrepancies at bay.


Stem Cell Therapy Market Segmentation


The stem cell therapy market has been divided based on cell source, type, application, and end user.


Cell Source:


The stem cell therapy market, on the basis of cell source, is segmented into adipose tissue, bone marrow, embryo/cord blood-derived, neural, IPSCs,and PPSCs.The adipose tissue segment accounted for the largest share of 35.29% in 2020.


Adipose Tissue


Adipose tissue or fatty tissue is a specialized connective tissue consisting of lipid-rich cells called adipocytes found mainly under the skin also in deposits between the muscles, around the heart, in the intestines, membrane folds of the intestine, and elsewhere.


Bone Marrow


Bone marrow is a spongy tissue found in the center of bones and contains Hematopoietic Stem Cells (HSCs). HSCs if damaged, may not become red blood cells, white blood cells, or platelets.


Embryo/Cord Blood-Derived


Embryonic Stem Cells (ESCs) are stem cells derived from the undifferentiated inner mass cells of a human embryo that has the ability to form cells of muscle, nerve, blood, and potentially any cell type that makes up the body. These cells have the capacity for self-renewal that makes them an attractive cell source for regenerative medicine.


Neural


Neural stem cells are the most primordial and uncommitted cells of the nervous system that can give rise to offspring cells that differentiate into neurons and glial cells.


Induced Pluripotent Stem Cells (IPSCS)


iPSCs (Induced pluripotent stem cells) are artificial stem cells produced from somatic cells that can self-renew indefinitely in culture and differentiate into all specialized cell types such as gametes.


Porcine Pluripotent Stem Cells (PPSc)


PPSCs can be used for various applications such as disease modeling, drug discovery, and regenerative medicine. These are divided and differentiated into multipotential hematopoietic stem cells of one of two lineages, including lymphoid progenitors or myeloid progenitors.


By Type


The stem cell therapy market, on the basis of type, is segmented into allogenic and autologous. The allogenic segment accounted for the largest share of 77.22% in 2020.



  • Allogenic


The increasing prevalence of cancer and related diseases among people createsa demand for allogeneic stem transplantation worldwide. According to WHO, around 300,000 new cancer cases are diagnosed each year among children aged 0-19 years. It is estimated that 19.3 million new cancer cases occurred in the year 2020. This creates a burden on the global health care system, creating demand for effective treatment options for cancers worldwide.



  • Autologous


Autologous stem cell transplantation, also known as autologous bone marrow transplant, involves using a patient’s own stem cells for the transplant. For this transplantation, stem cells are collected in advance from the patient and are frozen


By Application


The stem cell therapy market, on the basis of application, is segmented into diabetes, musculoskeletal disorders, cancer, cardiovascular disorders, gastrointestinal diseases, and others. The diabetes segment accounted for the largest share of 27.33% in 2020.



  • Diabetes:


According to WHO, about 422 million people have diabetes around the globe. The majority of diabetes cases are found in low- and middle-income countries. Diabetes mellitus, commonly known as diabetes, is a metabolic disease that occurs when blood glucose is too high. This condition leads over time to serious damage to the heart, eyes, blood vessels, nerves, and kidneys.



  • Musculoskeletal Disorders:


Musculoskeletal disorders are the conditions that affect the human body’s movement or musculoskeletal system, i.e., muscles, ligaments, tendons, discs, nerves, and blood vessels.



  • Cardiovascular


Cardiovascular disease is a class of heart and blood vessels diseases that include cerebrovascular disease, rheumatic heart disease, and other conditions.



  • Cancer


Cancer is a group of diseases that result when cellular changes cause the uncontrolled growth and division of cells and spread to other body parts.



  • Gastrointestinal Disease


Stem cell therapy provides hope for patients with all types of gastrointestinal diseases. This therapy helps repair damaged cells, alleviate inflammation and eliminate pain and discomfort. With the help of this therapy, there is a possibility of Gasterointestinal Infectious (GI) disease cure. Autologous stem cells are often used for stem cell therapy.



  • Others


Stem cell therapy can also be used to treat osteoarthritis, burns, spinal cord injuries, and many others. Researchers are working on the advancement of stem cells and their applications in various diseases. Stem cell therapy can be very useful in diseases where organs are damaged, or the immune system is too active. The use of numerous stem cells is being studied in the laboratory and experimental therapies.


By End User


The stem cell therapy market, on the basis of end user, is segmented into hospitals & clinics, academic research centers, and others. The hospitals & clinics accounted for the largest share of 46.57% in 2020.



  • Hospitals & Clinics


The growth of the stem cell therapy market in the hospital and clinics segment is driven by the increasing prevalence of skin disorders, including acne. As per the American Academy of dermatology association, nearly 85% of teenagers are affected by acne at some point during their teenage years, and over 50 million people have acne in the US in total.



  • Specialty Centers


The presence of advanced technologies and expert dermatologists in specialty centers is driving the segment. Furthermore, the increasing number of specialty care and the rise in spending on skincare is hugely driving the growth of the Stem Cell Therapy market in this segment. For instance, as per the American Academy of Dermatology Association, in 2013, the costs associated with the treatment among those who sought medical care for acne exceeded USD 1.2 billion.


Stem Cell Therapy Market Share (%), by Region, 2020


Stem Cell Therapy Market Share by Region 2020
Source: MRFR Analysis


Stem Cell Therapy Market Regional Analysis


The stem cell therapy market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.



  • Americas


The increased public-private financing and research grants for producing safe and effective stem cell therapy products and the presence of key players in the region are the major factors driving America’s stem cell therapy market. For instance, in April 2018, Sangamo Therapeutics, Inc., US, received a USD 8 million grant from the California Institute for Regenerative Medicine (CIRM) to evaluate ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta-thalassemia. The American stem cell therapy market is expected to record a CAGR of 10.99% from 2021 to 2027.



  • Europe


Europe holds the second largest market share due to an increase in the willingness of patients to undergo stem cell treatment and a growing number of cases of chronic and neurological disorders. For instance, according to GLOBOCAN’s Global Cancer Statistics 2020, there were an estimated 19.3 million new cancer cases and around 10 million cancer deaths found in 2020, out of which Europe accounted for 22.8% of the total cancer cases and 19.6% of total cancer deaths in 2020.



  • Asia-Pacific


Asia-Pacific is the fastest-growing regional market for stem cell therapies as it is developing rapidly and has witnessed the emergence of many players. Moreover, the rising prevalence of cancer, and growing adoption of stem cell therapy treatments in the region, are likely to drive the market’s growth. According to GLOBOCAN’s Global Cancer Statistics 2020, out of the estimated 19.3 million new cancer cases worldwide.Asia held the largest share of cases, with the prevalence of around 50% of total cancer cases and 58.3% of total cancer deaths in 2020.



  • Middle East & Africa


The stem cell therapy market in the Middle East& Africa is expected to witness restricted growth due to a lack of public awareness and limited affordability among the population. However, there are some regenerative medicine applications taking place in the Gulf countries. According to the Middle East Medical Portal Ltd. (UAE), in November 2018, there were two public stem cell banks present in Saudi Arabia, one public and one private cell bank in the UAE, and one public cell bank in Qatar. Most of the samples are stored in other regions, in countries like the UK and India.


List of Key Companies Covered in the Stem Cell Therapy Market Report



  1. Seraxis, Inc. (Germany)

  2. ViaCyte, Inc. (US)

  3. Betalin Therapeutics Ltd (Israel)

  4. 4.NextCell Pharma AB (US)

  5. Kadimastem (Israel)

  6. Vertex Pharmaceuticals (US)

  7. Fresenius Medical Care AG & Co. KGaA (Germany)

  8. Sernava Corp (Canada)

  9. Novo Nordisk A/S (Denmark)

  10. Generex Biotechnology (Canada)


Recent Developments



  • February 2022- Cynata Therapeutics, a cell therapeutics biotech, to get a patent covering its proprietary Cymerus™ mesenchymal stem cell, or "MSC" technology from China's patent office. The company anticipates receiving the patent by the end of May 2022 and is valid until March 2037.

  • January 2022- Gamida Cell, a prominent biotech company, has announced that it will be starting a rolling FDA submission for the blood cancer treatment omidubicel. Still, it seeks a little help from slashing staff and a strategic partner to get it across the finish line.

  • February 2022- Likarda, LLC, a cell therapy company developing innovative delivery systems, has announced an agreement with eQcell. The agreement includes exercise options for a worldwide license of the customized hydrogel encapsulation product for their equine multipotent stromal cells.


Report Overview:


The study covers the existing short-term and long-term market effects, helping decision-makers draft short-term and long-term plans for businesses by region. The report covers major regions in the Americas, Europe, Asia-Pacific, and Middle East & Africa. The report analyzes Market Drivers, Restraints, Opportunities, Challenges, Porter's Five Forces, Value Chain, and impact of COVID-19 on the market.


Scope of the Report and Market Segmentation


Stem Cell Therapy Market, by Cell Source



  • Adipose Tissue

  • Bone Marrow

  • Neural

  • Embryo/Cord Blood-Derived

  • IPSCs

  • PPSCs


Stem Cell Therapy Market, By Type



  • Allogenic

  • Autologous


Stem Cell Therapy Market, By Application



  • Cancer

  • Diabetes

  • Musculoskeletal Disorders

  • Cardiovascular

  • Gastrointestinal Diseases

  • Others


Stem Cell Therapy Market, by End User



  • Hospitals & Clinics

  • Ambulatory Surgical Centers (ASCs)

  • Academic and Research Centers

  • Others


Stem Cell Therapy Market, by Region



  • Americas

    • US

    • Canada




    • North America

    • Latin America


  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Rest of Western Europe




    • Western Europe

    • Eastern Europe


  • Asia-Pacific


    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific


  • Middle East & Africa


    • Middle East

    • Africa




Report Scope:
Report Attribute/Metric Details
  Market Size   2027: USD 11,607.49Million
  CAGR   10.74%
  Base Year   2020
  Forecast Period   2021-2027
  Historical Data   2018 & 2019
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Cell Source, Type, Application, End user and Region
  Geographies Covered   Americas, Europe, Asia-Pacific, Middle East and Africa
  Key Vendors   1.Seraxis, Inc. (Germany) 2. ViaCyte, Inc. (US) 3. Betalin Therapeutics Ltd (Israel) 4.NextCell Pharma AB (US) 5. Kadimastem (Israel) 6. Vertex Pharmaceuticals (US) 7. Fresenius Medical Care AG & Co. KGaA (Germany) 8. Sernava Corp (Canada) 9. Novo Nordisk A/S (Denmark) 10. Generex Biotechnology (Canada)
  Key Market Opportunities   â€¢ Development of stem cell therapy for the treatment of several hematologic and solid tumor types
  Key Market Drivers   â€¢ Increasing prevalence of chronic disorders • Growing Pharmaceutical industry and increasing spending in medical research • Increase in the number of clinical studies for stem cell therapy


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

The major factors are a better investment in research, increasing awareness related to therapeutic applications, the inclusion of advanced genetic analysis technologies, various disease management procedures, and others.

Difficulties regarding collection and storage can hamper market growth.

Stem cell therapy market would get backed by the Americas the most.

The players are MEDIPOST Co., Ltd. (South Korea), Osiris Therapeutics, Inc. (US), Holostem Terapie Avanzate S.r.l. (Italy), Anterogen Co., Ltd. (South Korea), Pharmicell Co., Ltd. (South Korea), NuVasive, Inc. (US), RTI Surgical, Inc. (US), JCR Pharmaceuticals Co., Ltd. (Japan), and AlloSource (US), Thermo Fisher Scientific, and others.

The segments are bone regeneration, medicine, cardiovascular diseases, treatment of eyes, neurodegenerative disorders, wound healing, metabolic disorders, hematopoietic disorders, immunodeficiency, cancer, and diabetes.